Evommune, Inc.
New York Stock ExchangeRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Evommune, Inc. (NYSE: EVMN) is a clinical-stage biotechnology company that discovers and develops innovative oral therapies targeting key drivers of chronic inflammatory diseases, including mast cell, sensory neuron, and T-cell activity. Founded in 2020 and headquartered in Palo Alto, California, the company advances a pipeline of differentiated product candidates, with lead program EVO756, a potent and highly selective small-molecule antagonist of mas-related G-protein coupled receptor X2 (MRGPRX2), in Phase 2b development for chronic spontaneous urticaria (CSU) and Phase 2 for chronic inducible urticaria (CIndU) and atopic dermatitis (AD); EVO301, an IL-18 targeted fusion protein, in development for AD and ulcerative colitis (UC); and additional preclinical programs for broader immune-mediated inflammatory conditions. Evommune operates primarily in the United States, focusing on patients with unmet needs in dermatology and gastroenterology segments where current therapies often provide symptomatic relief without addressing disease progression. In October 2024, Evommune completed a $115 million Series C financing co-led by RA Capital Management and Sectoral Asset Management to advance EVO756 and EVO301 clinical programs, including multiple Phase 2 data readouts expected in 2025 and 2026, and reported positive proof-of-concept data for EVO756 with full results presented in Q4 2024. In 2024, the company acquired EVO301 from South Korean biotech AprilBio for $15 million upfront and initiated a Phase 2b trial of EVO756 in moderate-to-severe CSU, which is Phase 3-enabling with data anticipated in mid-2026. Most recently, in November 2025, Evommune closed a $150 million initial public offering on the New York Stock Exchange, with full exercise of underwriters' option for additional shares, providing capital to fund ongoing clinical trials, expand discovery research, and support regulatory milestones.
Evommune Reports First Quarter 2026 Financial Results and Provides Business Highlights
Evommune, Inc. (EVMN) Discusses Scientific Rationale and Pipeline Expansion for MRGPRX2 Antagonist in Migraine Prevention Transcript
Evommune to Host KOL Webinar on April 13, 2026 Highlighting the Potential of MRGPRX2 Inhibition in Migraine
Capricorn Fund Managers Ltd Acquires Shares of 60,000 Evommune, Inc. $EVMN
Evommune, Inc. (NYSE:EVMN) Receives Average Rating of “Moderate Buy” from Analysts
1 Under‑the‑Radar Biotech to Buy for Potential 10X Growth in the Next Decade
Evommune Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Highlights
Evommune, Inc. (NYSE:EVMN) Receives Average Recommendation of “Moderate Buy” from Brokerages
Evommune Announces $125 Million Private Placement
Evommune Stock Cools Off After Big Rally On Successful Eczema Trial
Evommune's Stock Surges On Strong Results For New Eczema Drug
Evommune Nearly Doubles — Has Dupixent Met Its Match In Eczema?
Evommune Announces Positive Top-line Data from Phase 2a Proof-of-Concept Trial of EVO301 in Moderate-to-Severe Atopic Dermatitis
Evommune, Inc. (NYSE:EVMN) Given Consensus Recommendation of “Buy” by Analysts
High Risk, High Reward: 3 Healthcare Stocks to Watch in 2026
Evommune (NYSE:EVMN) Director Robert Lorne Hopfner Purchases 1,000 Shares
Evommune Reports Third Quarter 2025 Financial Results and Provides Business Update
Evommune Announces Pricing of its Initial Public Offering
Evommune Announces Commencement of Initial Public Offering